Page 21234..1020..»

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Posted: November 20, 2024 at 2:48 am

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA.

Link:
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Posted in Global News Feed | Comments Off on Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

Posted: November 20, 2024 at 2:48 am

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference.

Go here to read the rest:
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

Posted in Global News Feed | Comments Off on TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Posted: November 20, 2024 at 2:48 am

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed’s shareholders approved a consolidation of the Company’s common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company’s board of directors (the “Board”). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.

Go here to see the original:
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Posted in Global News Feed | Comments Off on Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Posted: November 20, 2024 at 2:48 am

Targeting Transformative Solutions for Aplastic Anemia and Beyond

Read more:
Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Posted in Global News Feed | Comments Off on Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXellerate™

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Posted: November 20, 2024 at 2:48 am

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York.

Excerpt from:
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Posted in Global News Feed | Comments Off on Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Posted: November 20, 2024 at 2:48 am

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

More:
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Posted in Global News Feed | Comments Off on Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Posted: November 20, 2024 at 2:48 am

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors.

More:
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Posted in Global News Feed | Comments Off on Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…

Posted: November 20, 2024 at 2:48 am

WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.

Link:
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance...

Posted in Global News Feed | Comments Off on Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance…

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Posted: November 20, 2024 at 2:48 am

FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program. This program is conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. This year’s program attracted thousands of nominations from 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.

Go here to see the original:
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

Posted in Global News Feed | Comments Off on Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Posted: November 20, 2024 at 2:48 am

November 20, 2024, 7:00 AM CET

See original here:
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Posted in Global News Feed | Comments Off on argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

Page 21234..1020..»